Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of Centene Corporation securities between December 12, 2024, and June 30, 2025, alleging misleading statements regarding the company's financial performance and enrollment rates [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that during the Class Period, Centene's management provided investors with overly positive information regarding expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year [5]. - Defendants allegedly made confident statements about Centene's enrollment and morbidity rates, as well as strong retention rates in its Medicare business, while concealing material adverse facts about the true state of these metrics [5]. Group 2: Participation Information - Investors who purchased Centene common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

SAN DIEGO, July 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Neogen Corporation (NASDAQ: NEOG) securities between January 6, 2023 and June 3, 2025. Neogen is a food safety company that manufactures and markets products and services dedicated to food and animal safety.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Inve ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Jasper Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On July 7, 2025, Jasper Therapeutics released updated data from its BEACON Phase 1b/2a study of briquilimab, indicating issues with a specific drug product lot that affected results in certain patient cohorts [3] - The stock price of Jasper Therapeutics fell by $3.73 per share, or 55.1%, closing at $3.04 per share following the announcement of the study results [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving WPP plc and its officers or directors [1] Financial Performance - On July 8, 2025, WPP reduced its 2025 guidance for like-for-like revenue less pass-through costs to a decline of 3% to 5% and anticipated a year-on-year decline in headline operating profit margin of 50 to 175 basis points, excluding foreign exchange effects [3] - WPP reported a deterioration in performance as the second quarter progressed, attributing this to a challenging economic backdrop and expected continued macro uncertainty affecting client spending and weaker net new business than initially anticipated [3] - Following the announcement, WPP's American Depositary Receipt (ADR) price fell by $6.48, or 18.09%, closing at $29.34 per ADR on July 9, 2025 [3]

Core Points - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud affecting investors between January 13, 2021, and July 28, 2024 [1][2] - The lawsuit claims that Reckitt's cow's milk-based formula, Enfamil, posed an increased risk of NEC in preterm infants, which was not disclosed, impacting sales and exposing the company to legal claims [2] - Investors have until August 4, 2025, to request to be appointed as lead plaintiff, with no costs required for participation in the lawsuit [3] Company Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Centene Corporation (“Centene” or the “Company”) (NYSE: CNC) securities between December 12, 2024 to June 30, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CENTENE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO ...

RADNOR, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Centene Corporation (“Centene”) (NYSE: CNC) on behalf of those who purchased or otherwise acquired Centene securities between December 12, 2024, and June 30, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is September 8, 2025. ...

Core Viewpoint - A class action lawsuit has been filed against Broadmark Realty Capital Inc. and Ready Capital Corporation for alleged violations of federal securities laws related to their merger [1][2]. Group 1: Lawsuit Details - The lawsuit seeks damages for investors who held Broadmark common stock as of May 30, 2023, the date of the merger with Ready Capital [2]. - The complaint alleges that the proxy statement soliciting shareholder support for the merger contained false or misleading statements and failed to disclose significant financial distress among borrowers in Ready Capital's portfolio due to high interest rates [3]. - It is claimed that an oversupply of multifamily properties limited the ability of Ready Capital borrowers to raise rents to cover growing debt costs [3]. - A major development project acquired during the merger, valued at approximately $500 million, faced severe setbacks including cost overruns and construction delays, which were not disclosed [3]. - As a result of these issues, Ready Capital's expected credit losses and financial projections were materially understated [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Broadmark have until July 28, 2025, to request to be appointed as lead plaintiff in the class action [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - A class action lawsuit has been initiated against Fortrea Holdings Inc. due to allegations of materially false and misleading statements regarding the company's business operations and financial prospects [1] Summary by Relevant Sections Allegations - The lawsuit claims that Fortrea Holdings overestimated the revenue contributions from Pre-Spin Projects for 2025 earnings [1] - It is alleged that the company overstated potential cost savings from exiting Transition Services Agreements (TSAs) [1] - The previously announced EBITDA targets for 2025 are claimed to be inflated as a result of these misstatements [1] - The viability of the company's post-Spin-Off business model and its financial prospects were also allegedly overstated [1] - Overall, the company's public statements are described as materially false and misleading throughout the relevant period [1]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].